Corrigendum

In the Drug Evaluation Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality published in the March 2006 issue of Expert Opinion on Pharmacotherapy (Expert Opin. Pharmacother. (2006) 7(4):463-476) the sentence that reads ‘A direct head-to-head comparison with rosiglitazone showed significantly different effects of both drugs, with a decrease of the triglycerides with pioglitazone by 20.3% (rosiglitazone: +5.6%, p < 001 versus pioglitazone), an increase in total cholesterol by 4.6% (rosiglitazone: +14.6%, p < 0.001) and LDL cholesterol by 12% (rosiglitazone: +20%, p < 001), and an increase in HDL cholesterol by 13% (rosiglitazone: +6%, p < 0.001) [14].’ should have read ‘A direct head-to-head comparison with rosiglitazone showed significantly different effects of both drugs, with a decrease of the triglycerides with pioglitazone by 20.3% (rosiglitazone: +5.6%, p < 0.001 versus pioglitazone), an increase in total cholesterol by 4.6% (rosiglitazone: +14.6%, p < 0.001) and LDL cholesterol by 12% (rosiglitazone: +20%, p < 0.001), and an increase in HDL cholesterol by 13% (rosiglitazone: +6%, p < 0.001) [14].’